pI: 8.4205 |
Length (AA): 693 |
MW (Da): 79421 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 692 | 2xau (A) | 27 | 730 | 38.00 | 0 | 1 | 1.45593 | -0.55 |
455 | 689 | 3i4u (A) | 950 | 1182 | 36.00 | 0 | 1 | 0.838605 | -0.81 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_130943)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G18465 | ATP-dependent RNA helicase DDX35 |
Brugia malayi | Bm1_47285 | Probable ATP-dependent helicase DHX35 |
Caenorhabditis elegans | CELE_Y67D2.6 | Protein Y67D2.6 |
Dictyostelium discoideum | DDB_G0269306 | DEAD/DEAH box helicase |
Drosophila melanogaster | Dmel_CG3225 | CG3225 gene product from transcript CG3225-RA |
Homo sapiens | ENSG00000101452 | DEAH (Asp-Glu-Ala-His) box polypeptide 35 |
Loa Loa (eye worm) | LOAG_08526 | hypothetical protein |
Loa Loa (eye worm) | LOAG_01504 | DEAH box polypeptide 35 |
Mus musculus | ENSMUSG00000027655 | DEAH (Asp-Glu-Ala-His) box polypeptide 35 |
Oryza sativa | 4325567 | Os01g0212100 |
Schmidtea mediterranea | mk4.003651.01 | Putative atp-dependent RNA helicase |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Hepatitis C virus genotype 3a (isolate NZL1) (HCV) | Genome polyprotein | Compounds | References |
Hepatitis C virus genotype 1b (strain HC-J4) (HCV) | Genome polyprotein | Compounds | References |
Hepatitis C virus | NS3 | Compounds | References |
Hepatitis C virus genotype 1a (isolate 1) (HCV) | Hepatitis C virus polyprotein | Compounds | References |
Hepatitis C virus genotype 1b (isolate BK) (HCV) | Genome polyprotein | Compounds | References |
Hepatitis C virus genotype 1b (isolate Con1) (HCV) | Genome polyprotein | Compounds | References |